Interview with Kalman Petro, Managing Director, Actavis BV
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Address: Wilgenlaan 5 • 1161 JK Zwanenburg,Netherlands
Tel: 31 (0) 20 / 407 20 72
Web: http://www.daiichi-sankyo.nl/
DAIICHI SANKYO’s goal is to establish itself as a ‘Global Pharma Innovator.’ The pharmaceutical industry is one of the 21st century’s growth industries, and what this vision of the company signifies is DAIICHI SANKYO making it the leading industry of Japan, a nation built on the platform of scientific and technological creativity, and establishing itself as a firm presence by continued success as a flagship company. This is the vision that guides the development of our global pharmaceutical operations.
DAIICHI SANKYO’s products are used not only in Japan but also in many parts of the world including Asia, Europe and the United States. To pick up on global needs all over the world and have these reflected in global pharmaceutical operations, we are active in promoting information exchange in a number of areas including research and development, supply chain management and marketing.
We are determined to contribute to the health of people everywhere by creating new medicines in popular use throughout the world, and delivering them to places where medical treatment is required, transcending national borders.
We have about 2,300 overseas medical representatives in 33 locations, mainly in Europe and the United States. From this point on, we are aiming for growth through our own development and sales, mainly in the United States, and to this end, we are planning to expand our overseas development and sales bases. While making efforts to develop innovative new medicines, we have become established as a firm presence in the global market for pharmaceutical products by implementing the highest standard of operational efficiency in the industry in order to ‘respond to the medical needs of people everywhere.’
Our U.S. subsidiary, Daiichi Sankyo, Inc. (DSI) has research and development and sales sections, and as the organization that forms the nucleus of our U.S. operations, is expected to grow in the future.
Our European subsidiary, Daiichi Sankyo Europe GmbH (DSE), is headquartered in Munich, Germany, and has around 800 medical representatives in operational bases in 10 European countries.
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination…
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
As the founder of the Institute of Young Entrepreneurs at the Delft University of Technology and an enthusiastic promoter of innovation and new technologies, what do you believe distinguishes a…
We do not often meet companies that have been successful at retaining their manufacturing facilities in the Netherlands. How and why did former Katwijk Farma -and now Apotex- succeed to…
Pfizer is well placed for the next generation of growth. Coming off great M&A’s and now restructuring internally, (from the country structure to the business units). After closing 2010, the…
Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths…
While doing our research we couldn’t help but notice that you are quite passionate about issues related to healthcare and an avid proponent of healthcare reform. In this vein, what…
IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market?…
As the chairman of a consortium that has been working towards both medical and technological progress in the region, how have you seen this progress taking place in the Netherlands…
Deloitte is renowned for its strong network of international expertise. Yet every market has its own particularities… Having spent 16 years with the company, in your opinion, what is it…
Your role as Chair of the Executive Board is a mix between CEO and CMO. On a daily basis, which do you see yourself as more – the Chief Executive…
See our Cookie Privacy Policy Here
